Real-World Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Combination Therapy on Weight Management Within a Digital-Supported Shared Care Model for Type 2 Diabetes
Authors' conclusion
Sodium-glucose cotransporter-2 inhibitors and GLP-1RA combination therapy provides superior weight management in patients with overweight/obese type 2 diabetes, with effects enhanced by digital shared care model.
Study context
- Population
- Patients with overweight/obese T2D at a diabetes shared care clinic with a digital shared care model (2022–2025)
- Participants
- 921 patients
- Exposure
- SGLT2i, GLP-1 RA, SGLT2i + GLP-1 RA combination therapy vs control
- Outcome
- Changes in body weight, BMI, waist circumference and HbA1c
- Follow-up
- Median 1.84 years
Methodological detailsreal-world, single-clinic digital shared care model
- Real-world
- Single-clinic digital shared care model
Main finding
As reported in the abstract
median 1.84 years
Greatest median weight reduction: Combination therapy
5.1%; 4.0 kg
Largest HbA1c reduction: GLP-1RA monotherapy
−1.20%
Observational data: associations, not effects.
Further findings
Odds of ≥5% weight loss in combination group after adjusting for digital engagement
- Increase in odds of ≥5% weight loss with Combination therapy after adjustment for digital engagement
- 5.02%
Predictors of weight loss success
- Higher baseline BMI and longer diabetes duration predicted weight loss success; higher baseline HbA1c was negatively associated
Original publication
Real-World Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Combination Therapy on Weight Management Within a Digital-Supported Shared Care Model for Type 2 Diabetes. Endocr Pract. Published 6 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →